Jebrak G
Service de pneumologie B, hôpital Bichat, 46, rue Henri-Huchard, 75018 Paris, France.
Rev Mal Respir. 2010;27(1):11-8. doi: 10.1016/j.rmr.2009.08.002. Epub 2009 Dec 30.
COPD management guidelines have been proposed to improve the major outcomes for COPD patients. In clinical practice, COPD treatment is only partially consistent with current guidelines and recommendations.
Global initiative for chronic obstructive lung disease (GOLD) guidelines are based on a COPD severity scale and are subject to change as the evidence based evolves. The main purpose of our study was to access whether the treatments prescribed to patients with COPD were consistent with these guidelines.
Treatments prescribed by French physicians to 542 patients with COPD in stable conditions were recorded according to the severity of obstruction, using GOLD classification. We compared our prescription data base with the GOLD guidelines.
Forty percent of the initial physicians were chest specialists.
78.3 % men, (64.8+/-10.8years) and 25 % were still smokers at inclusion. We found an important discrepancy between recommended treatment and COPD severity. Bronchodilators were commonly prescribed, but 11 % in severe COPD (stages III and IV) did not receive them. Inhaled steroids (ICS) were used respectively in 55.2 %, 59.4 % of patients in stages I, II (FEV1>50 %) (for whom they are not recommended) and 77.4 and 85.3 % in stages III and IV. Only 30 % of patients used ICS+beta2 agonists in the same device. Influenza vaccination had been performed in only half of patients whatever the severity of COPD. Pulmonary rehabilitation had been used by 10 % of patients, (stage II: 6.4 %, stage III: 9.6 %, stage IV: 20.6 %).
We confirmed that there are discrepancies between COPD guidelines and routine treatments. Some treatments such as ICS were overused in mild phenotypes, whereas in a high proportion of cases influenza immunisation and rehabilitation were omitted.
慢性阻塞性肺疾病(COPD)管理指南已被提出以改善COPD患者的主要预后。在临床实践中,COPD治疗仅部分符合当前指南和建议。
慢性阻塞性肺疾病全球倡议(GOLD)指南基于COPD严重程度分级,且会随着循证医学的发展而变化。我们研究的主要目的是评估给COPD患者开具的治疗方案是否符合这些指南。
根据GOLD分级,记录法国医生给542例稳定期COPD患者开具的治疗方案,依据阻塞严重程度进行分类。我们将我们的处方数据库与GOLD指南进行了比较。
最初的医生中有40%是胸科专家。
78.3%为男性,(年龄64.8±10.8岁),纳入时25%仍在吸烟。我们发现推荐治疗与COPD严重程度之间存在重要差异。支气管扩张剂通常会被开具,但重度COPD(III期和IV期)患者中有11%未接受此类治疗。吸入性糖皮质激素(ICS)在I期、II期(FEV1>50%)患者中的使用比例分别为55.2%、59.4%(这两个阶段不推荐使用),在III期和IV期患者中的使用比例分别为77.4%和85.3%。只有30%的患者使用了同一装置中的ICS加β2激动剂。无论COPD严重程度如何,只有一半的患者接种了流感疫苗。10%的患者接受了肺康复治疗,(II期:6.4%,III期:9.6%,IV期:20.6%)。
我们证实了COPD指南与常规治疗之间存在差异。一些治疗,如ICS,在轻度表型中被过度使用,而在很大比例的病例中,流感免疫接种和康复治疗被遗漏。